Integra LifeSciences Holdings Co (NASDAQ: IART) has reported E.P.S. of $-0.04 for its first fiscal quarter (ending March 31) versus $0.30 for the same period a year ago — a decline of -113%. This result fell short of the consensus estimate of $0.76 by $-0.80. For the latest four quarters through March 31, E.P.S. were $0.51 versus $2.08 for the same period a year ago — a decline of -75%.
Recent Price Action
On 5/6/24, Integra LifeSciences Holdings Co (NASDAQ: IART) stock suffered a major decline of -19.9%, closing at $23.14. Moreover, exceptionally high trading volume at 628% of normal accompanied the decline. Relative to the market the stock has been weak over the last nine months and has declined -18.3% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to exceed the cost of capital, IART is expected to continue to be an important Value Builder.
Integra LifeSciences Holdings has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing contradictory signals. Integra LifeSciences Holdings has a slightly positive Appreciation Score of 62 but a poor Power Rating of 18, producing the Negative Value Trend Rating.
Rating Review
In light of this discouraging new earnings information and highly negative price change we are reviewing our current Overall Rating of D. We would continue to view the shares with caution pending completion of this review in the next several days.
Be the first to comment